title: Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: development of recommendations for clinical practice based on data from the literature and experts opinion.
abstract: OBJECTIVE
  To develop recommendations about treatment (except anti-TNF agents) of psoriatic arthritis with peripheral joint involvement (PsA) seen in everyday practice, using evidence from the literature, supplemented with expert opinion when needed.
  
  
  METHODS
  The recommendations were based on evidence from the literature. First, a scientific committee used a Delphi procedure to select five focal points of interest. Then, a literature task force looked for relevant publications in the following: Cochrane, Pubmed, and Ovid databases and abstracts from the French Society for Rheumatology, European League against Rheumatism and American College of Rheumatology. Based on the data from these publications, recommendations were drafted and then validated by a group of 68 experts. The strength of each recommendation was determined, as well as the extent of agreement among the experts.
  
  
  RESULTS
  The evidence extracted from 73 selected papers was presented to experts during interactive workshops. At the end of the workshops, the experts drafted six recommendations, which were then validated by a final vote including all participants. These six recommendations displayed various strength from B to D.
  
  
  CONCLUSIONS
  These recommendations should help to improve practice uniformity and, ultimately, to improve the management of PsA in France.
authors.affiliation: Service de Rhumatologie, Centre Hospitalier, Le Mans, France.
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Dernis
authors.forename: Frédéric
authors.initials: F
authors.lastname: Lavie
authors.forename: Carine
authors.initials: C
authors.lastname: Salliot
authors.forename: René-Marc
authors.initials: RM
authors.lastname: Flipo
authors.forename: Alain
authors.initials: A
authors.lastname: Saraux
authors.forename: Jean-Francis
authors.initials: JF
authors.lastname: Maillefert
authors.forename: Carle
authors.initials: C
authors.lastname: Paul
authors.forename: Philippe
authors.initials: P
authors.lastname: Goupille
authors.forename: Alain
authors.initials: A
authors.lastname: Cantagrel
authors.forename: Pascal
authors.initials: P
authors.lastname: Claudepierre
authors.forename: Philippe
authors.initials: P
authors.lastname: Gaudin
authors.forename: Jacques
authors.initials: J
authors.lastname: Tebib
authors.forename: Daniel
authors.initials: D
authors.lastname: Wendling
authors.forename: Thierry
authors.initials: T
authors.lastname: Schaeverbeke
authors.forename: Xavier
authors.initials: X
authors.lastname: Le Loët
authors.forename: Bernard
authors.initials: B
authors.lastname: Combe
mesh_terms: D026683:Advisory Committees; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000188:drug therapy*; D001379:Azathioprine / Q000627:therapeutic use; D019317:Evidence-Based Medicine / Q000379:methods; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use; D006784:Hospitals, Teaching; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use; D007596:Joints / Q000473:pathology; D000077339:Leflunomide; D010919:Placebos; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D005938:Glucocorticoids; D007555:Isoxazoles; D010919:Placebos; D000077339:Leflunomide; D001379:Azathioprine